TricValve for severe tricuspid regurgitation
Part of Heart & circulation clinical trials.
This trial is testing a new device called the TricValve to treat severe tricuspid regurgitation (a leaky heart valve on the right side). It is for people who still have symptoms despite taking heart failure medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have severe tricuspid regurgitation (leaky heart valve) confirmed by a heart ultrasound.
- You have heart failure symptoms that affect your daily life or you were hospitalized for heart failure in the past 6 months.
- You have been on heart failure medications (including a water pill) for at least 30 days.
- Your heart's pumping function (LVEF) is above 30%.
- You are not pregnant, planning pregnancy, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a catheter-based procedure (done through the blood vessels) to repair a severely leaky tricuspid valve. It may help people with symptoms or past hospitalizations from tricuspid valve leakage who are higher-risk for standard surgery.
This trial tests how well a new catheter-based valve system works for people with severe (or worse) tricuspid valve leaking who still have symptoms despite medicines. It aims to improve outcomes by treating the leaking valve without open-heart surgery, if your heart structure and overall health fit the study.
This trial tests a new, less invasive valve device (TricValve) for people with severe tricuspid regurgitation who are not good candidates for open-heart surgery. It aims to see if this device can help your heart pump better and improve your symptoms.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
This trial tests a new device, called the Laplace TTVR System, to replace the tricuspid valve in people whose leaky valve (tricuspid regurgitation) continues to cause symptoms despite medical treatment. It may help if you have severe symptoms and are not a candidate for open-heart surgery.
Hear when a new Tricuspid Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.